JOURNEY MEDICAL CORPOR

5,5500

27-ноября-24 15:45:00

15 мин. задержка

Акции

0,0000

0,00%

Сегодняшний диапазон

5,3000 - 5,6900

ISIN

N/A

Источник

NASDAQ

NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

20 дек 2023 12:19:59 Источник NetDania Notify
NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

19 дек 2023 08:45:11 Источник NetDania Notify
NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

18 дек 2023 09:50:29 Источник NetDania Notify
NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

07 дек 2023 08:45:04 Источник NetDania Notify
NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

06 дек 2023 09:26:29 Источник NetDania Notify
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

06 дек 2023 07:00:51 Источник Nasdaq GlobeNewswire
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

07 ноя 2023 15:01:18 Источник Nasdaq GlobeNewswire
Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

31 окт 2023 07:30:12 Источник Nasdaq GlobeNewswire
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)

20 окт 2023 07:30:59 Источник Nasdaq GlobeNewswire
Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations

06 сен 2023 07:00:04 Источник Nasdaq GlobeNewswire
Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

08 авг 2023 15:01:33 Источник Nasdaq GlobeNewswire
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

02 авг 2023 15:01:42 Источник Nasdaq GlobeNewswire
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023

19 июл 2023 07:30:00 Источник Nasdaq GlobeNewswire
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

11 июл 2023 07:30:20 Источник Nasdaq GlobeNewswire
Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023

03 июл 2023 07:00:00 Источник Nasdaq GlobeNewswire
Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

13 июн 2023 07:30:59 Источник Nasdaq GlobeNewswire
Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

22 май 2023 15:01:31 Источник Nasdaq GlobeNewswire
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

19 май 2023 15:01:27 Источник Nasdaq GlobeNewswire
Journey Medical Corporation Announces Postponement of First Quarter Financial Results Release and Conference Call

11 май 2023 15:01:01 Источник Nasdaq GlobeNewswire
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

04 май 2023 08:00:26 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.